News | February 09, 2015

ISET Discusses Minimally Invasive Clip to Repair Mitral Valve Regurgitation

Approximately one-third of patients who have the procedure need more than one clip to correct the problem

Heart failure, MitraClip, International Symposium on Endovascular Therapy

Image courtesy of Abbott Vascular


February 9, 2015 — A minimally invasive procedure to repair severe mitral valve regurgitation by clipping together the valve’s leaflets can improve function and quality of life and reduce the risk of hospitalization, research shows. Approximately one-third of patients who have the procedure need more than one clip to correct the problem, suggest data presented at the 27th annual International Symposium on Endovascular Therapy (ISET).

Mitral valve prolapse is a common condition in which the valve’s leaflets do not close properly. Many people with the condition never have symptoms, but in severe cases the blood leaks backward into the left atrium of the heart. About 250,000 people a year are diagnosed with this condition, called mitral valve regurgitation, which can cause shortness of breath, dizziness, fatigue and an irregular heartbeat. Recently approved by the U.S. Food and Drug Administration (FDA), the MitraClip holds together the valve’s leaflets to reduce the degree of regurgitation.

“In many cases one clip is sufficient; however in one-third of the patients additional clips are necessary to reduce the degree of regurgitation without producing stenosis, making the valve too tight,” said Ramon Quesada, M.D., medical director of Interventional Cardiology & Cardiac Research for the Miami Cardiovascular Institute.

Quesada was an investigator in the EVEREST II trial, which enrolled 279 patients with severe mitral valve disease. Patients were randomized to either undergo surgical repair (95 patients) or to have the clip placed (184 patients). In the subgroup of patients who were at high risk for surgical repair it was found that the Mitraclip procedure was beneficial because it improved the patient’s cardiovascular function and reduced the rate of hospitalization for heart failure.

Mitral valve regurgitation (also called mitral valve prolapse) is the most common type of heart valve problem in the United States. Every year, about 50,000 people have a severe enough problem that they require surgery, which is the “gold standard” treatment. However, open-heart surgical valve repair is a major procedure requiring heart-lung bypass and prolonged anesthesia. The valve is then replaced or repaired using a variety of techniques. Because many of these patients are older, surgery is often considered too high risk. In the non-surgical transcatheter treatment with MitraClip, the physician threads a catheter through the arteries and advances a clothespin-like clip into the heart’s left atrium where it is positioned to clasp the leaflets together, allowing blood to continue flowing but not back up into the atrium. The device is made of metal and covered with a polyester fabric.

For more information: www.iset.org

 

 


Related Content

News | Heart Valve Technology

April 17, 2024 —CPR Therapeutics, Inc. (CPR-T), an early-stage medtech startup funded by the N.I.H and N.S.F to develop ...

Home April 17, 2024
Home
News | Heart Valve Technology

April 1, 2024 — Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health ...

Home April 01, 2024
Home
News | Heart Valve Technology

January 4, 2024 — Findings from a published case series research letter by the Henry Ford Health Structural Heart ...

Home January 04, 2024
Home
News | Heart Valve Technology

December 22, 2023 — TRiCares SAS (“TRiCares”), a privately held pioneer in the field of minimally invasive treatment of ...

Home December 22, 2023
Home
News | Heart Valve Technology

December 18, 2023 — Death rates related to infective endocarditis declined in most adults across the U.S. within the ...

Home December 18, 2023
Home
News | Heart Valve Technology

December 12, 2023 — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement ...

Home December 12, 2023
Home
News | Heart Valve Technology

November 20, 2023 — Abbott announced new late-breaking data that show advanced heart failure patients living with its ...

Home November 20, 2023
Home
News | Heart Valve Technology

October 24, 2023 — Abiomed, part of Johnson & Johnson MedTech[1], announced that novel data from seven research studies ...

Home October 24, 2023
Home
News | Heart Valve Technology

October 17, 2023 — The Patel Children's Heart Institute at St. Joseph's Children's Hospital achieved a milestone ...

Home October 17, 2023
Home
Subscribe Now